Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 16, 2021 16:05 ET | Source: Morphic Therapeutic

Morphic Therapeutic to Participate in GI/Microbiome Panel Discussion at the 41st Annual Cowen Health Care Conference

WALTHAM, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
January 05, 2021 08:00 ET | Source: Morphic Therapeutic

Morphic Expands Research and Development Collaboration with Janssen Through Third Integrin Program

WALTHAM, Mass. , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
December 30, 2020 08:00 ET | Source: Morphic Therapeutic

Morphic Therapeutic to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced that Praveen Tipirneni, M.D.,...
December 04, 2020 08:00 ET | Source: Morphic Therapeutic

Morphic Therapeutic Announces Appointment of Dr. Martin W. Edwards as Member of its Board of Directors

WALTHAM, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced the appointment of Dr. Martin W....
November 17, 2020 09:05 ET | Source: Morphic Therapeutic

Morphic Therapeutic to Present at the Jefferies Virtual London Healthcare Conference

WALTHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment...
November 09, 2020 07:00 ET | Source: Morphic Therapeutic

Morphic Announces Corporate Highlights and Third Quarter 2020 Financial Results

Initiated phase 1 clinical trial for MORF-057 with results expected by mid-2021 Presented data at UEG 2020 that reinforce preclinical potency and selectivity profile of MORF-057 Received $20 million...
October 12, 2020 07:00 ET | Source: Morphic Therapeutic

Morphic Announces Presentation of New Data Supporting Development of MORF-057 at UEG Week Virtual 2020

-Data validate physiologically relevant assay used in MORF-057 Phase 1 studies to measure receptor occupancy of α4β7 integrin--MORF-057, inhibitor of α4β7 integrin, in development to treat...
September 23, 2020 06:30 ET | Source: Morphic Therapeutic

Morphic Therapeutic Announces First Healthy Volunteers Dosed in Phase 1 Clinical Trial of MORF-057

First orally available integrin inhibitor from MInT Platform to enter the clinicMORF-057, inhibitor of α4β7 integrin, in development to treat inflammatory bowel diseasePhase 1 program to assess safety...
September 21, 2020 16:45 ET | Source: Morphic Therapeutic

Morphic Therapeutic to Present at the Jefferies Next Generation IBD Therapeutics Virtual Summit

WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment...
September 03, 2020 16:30 ET | Source: Morphic Therapeutic

Morphic Announces Participation in Upcoming Investor Conferences

WALTHAM, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...